Drug intelligence / Profile preview

HBVZ10

Development stage: Preclinical
Lead developer: HBVtech
Modality: Gene Therapies
Administration: Intramuscular

Overview

HBVZ10 is an adeno-associated virus serotype 8 (AAV8) vector-based gene therapy candidate developed by HBVtech for the treatment of chronic hepatitis B virus (HBV) infection. It is designed to deliver human anti-hepatitis B surface antigen (anti-HBs) antibody genes to skeletal muscle cells, enabling sustained, high-level endogenous production of neutralizing anti-HBs antibodies. By continuously neutralizing extracellular virions and reducing the circulating HBsAg burden, HBVZ10 blocks de novo infection and prevents the replenishment of the intrahepatic covalently closed circular DNA (cccDNA) pool. Preclinical studies have demonstrated that combining HBVZ10 with the nucleoside analog entecavir leads to significant synergistic reductions in hepatic cccDNA and relaxed circular DNA (rcDNA), promoting HBsAg seroclearance.

Other names: AAV-anti-HBs vector

Beyond the preview

Go deeper on HBVZ10.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HBVZ10.